News & Views

Filter By:

  • In a phase I trial, the combination of dabrafenib, trametinib and spartalizumab uncovers the crosstalk between the MAPK pathway and the immune system, which offers a promising new strategy to improve clinical outcomes.

    • Elena Elez
    • Javier Ros
    • Josep Tabernero
    News & Views
  • A study showing feasibility and preliminary efficacy of off-the-shelf CAR T cells represents steady progress on the long road to clinical use.

    • Jennifer N. Brudno
    • James N. Kochenderfer
    News & Views
  • As another clinical trial of a mitochondria-targeting cancer therapy faces failure, it calls for a thorough re-evaluation of the strategy; the time has come to go from the bedside back to the bench.

    • Xue Zhang
    • Chi V. Dang
    News & Views
  • A phase 1 trial using an allogeneic stem-cell-based therapy in people with progressive multiple sclerosis (MS) shows the feasibility and tolerability of the approach; rigorous evaluation of this and other regenerative strategies for MS is now urgently needed.

    • Valentina Fossati
    • Luca Peruzzotti-Jametti
    • Stefano Pluchino
    News & Views
  • Automated insulin delivery systems that are already used in type 1 diabetes show promise for patients with type 2 diabetes, and are poised to have a substantial effect on public health.

    • Roy W. Beck
    News & Views
  • Embryo culture during assisted reproduction treatment may be associated with altered risks for health and aging across the lifespan of the offspring.

    • Daniel R. Brison
    News & Views
  • A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.

    • Caroline Robert
    • Stéphan Vagner
    • Xavier Mariette
    News & Views
  • Osteoarthritis is highly heterogeneous, so effective therapies will need to target clearly defined molecular endotypes, restore mechanical joint function and reduce pain; thus, a ‘one-size-fits-all’ approach is unlikely to succeed.

    • Nicole Schäfer
    • Susanne Grässel
    News & Views
  • Circulating tumor DNA (ctDNA) informs predictive biomarkers in non–small-cell lung cancer, but the presence of ctDNA itself could also be a prognostic indicator.

    • Ana Vivancos
    • Josep Tabernero
    News & Views
  • In a clinical trial, non-nutritive sweeteners — which are supposedly inert — were shown to disrupt the gut microbiome of healthy people and impair glucose tolerance.

    • Tiphaine Le Roy
    • Karine Clément
    News & Views
  • Although questions remain about several diet and disease associations, current evidence supports dietary guidelines to limit red meat and increase vegetable intake.

    • Tammy Y. N. Tong
    • Keren Papier
    • Timothy J. Key
    News & Views
  • New analyses are prompting a shift in how we think about systolic blood pressure, with substantial benefits to be gained from population-wide interventions alongside targeting high-risk groups.

    • Panniyammakal Jeemon
    • Sivadasanpillai Harikrishnan
    News & Views
  • Emerging evidence shows that boosting with updated mRNA vaccines that target SARS-CoV-2 variants stimulates better neutralizing antibody responses than homologous boosters.

    • Deepta Bhattacharya
    • Gabriel D. Victora
    News & Views
  • A phase 2 study fails to meet its primary endpoint, but the treatment — a glucagon receptor antagonist — shows clinically relevant improvements in glycemic control, warranting further investigation as a potential adjunct to insulin.

    • Michelle Van Name
    • Jennifer Sherr
    News & Views
  • Following a single infusion of CD19-targeting CAR T cells, five patients with SLE showed reduction in disease activity and disease markers; long-term follow-up of these patients and larger trials are now key priorities.

    • Jane E. Salmon
    News & Views
  • Using comprehensive single-cell profiling, two studies reveal the molecular phenotypes of CAR T cells associated with durable response in patients with lymphoma, and highlight the role of CAR regulatory T cells in mediating resistance.

    • Neeraj Saini
    • Sattva S. Neelapu
    News & Views